140 posters, 10 videos, 15 audios, 20 sessions, 508 authors, 204 institutions
ePostersLive by SciGen Technologies S.A. All rights reserved.
8th World Congress on Vascular Access 2024
April 17 - 19, 2024 | Prague, Czech Republic
190
One institution’s experience with the implantation of long-term central venous devices in patients with mediastinal lymphadenopathy
Part of Topic
One institutions´ experience with implantation of long-term central venous devices placements in patients with mediastinal lymphadenopathy
Rázus M, Kašperová B, Slopovský J, Schweighoffer Bednariková E, Brezáni A, Gerešová S, Chovancová K
Department of Oncohematology, Comenius University and National Cancer Institute,
Bratislava, Slovakia
Mediastinal lymphadenopathy in aggressive lymphomas poses challenges in implanting long-term central venous access devices (LCVADs), largely due to central vein compression, increased thrombosis risk, and superior vena cava syndrome (SVC). Intensive anticancer therapy requires a high-quality long-term central venous catheter, which allows the patient adequate therapy from the beginning.
A retrospective analysis was conducted on lymphoma patients with LCVADs. This included also patients with SVC and significant mediastinal masses, tracking from LCVADs insertion to removal or follow-up end. Since April 2019, when we started implanting long-term vascular accesses, until the end of 2023 we implanted a total of 1530 accesses at the National Oncology Institute in Bratislava of which 104 patients had a mediastinal mass.